Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37384 | 0.79 | DPP4 (0.66) | DPP4XDHPDPK1GDAADORA3 | |
| Xanthine SCHEMBL9443819 | 0.79 | GDA (0.44) | DPP4XDHPDPK1GDAADORA3 | |
| Xanthine SCHEMBL4966 | 0.79 | GDA (0.44) | DPP4XDHPDPK1GDAADORA3 | |
| Hydrochloric Acid SCHEMBL4763244 | 0.78 | DPP4 (0.63) | DPP4XDHPDPK1GDAADORA3 | |
| Xanthine SCHEMBL7044234 | 0.78 | GDA (0.42) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL8719273 | 0.78 | DPP4 (0.63) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL11456967 | 0.78 | DPP4 (0.63) | DPP4XDHPDPK1GDAADORA3 | |
| Isoguanine SCHEMBL29569323 | 0.76 | PDPK1 (0.66) | DPP4XDHPDPK1GDAPOLA1 | |
| SCHEMBL833645 | 0.76 | GDA (0.41) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL9465644 | 0.76 | GDA (0.41) | DPP4XDHPDPK1GDAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | DPP4 624/4885XDH 253/4885PDPK1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.